Pediatrics

Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

An FDA-approval of Omalizumab would help reduce allergic reactions among 17 million people in the United States who have confirmed food allergies.

Tralokinumab is the first form of atopic dermatitis treatment that targets the interleukin-13 cytokine, the main source of atopic dermatitis symptoms.

Immunizations against influenza, COVID-19, and RSV are lower than they were this time last year, and hospitalizations have increased across all age groups.

According to a poster presented at ASHP Midyear 2023, stress ulcer prophylaxis (SUP) did not increase adverse effects, suggesting limited preventive benefits for gastrointestinal bleeding (GIB) in neonates.

The FDA is advising health care professionals who administer the vaccine to make sure the correct volume of the vaccine is withdrawn from the vial and the correct dose is administered to the patient.

A poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition, featured a complex pediatric case involving SARS-CoV-2, bacterial coinfection, multiorgan failure, thrombotic microangiopathy, and systemic hyperinflammation.

Unlike traditional THC, which is federally banned, D8 has managed to find a legal loophole, making it widely accessible.

Research findings may support further COVID-19 vaccination in children.

A refresher on best interventions for common respiratory disorders in children.

Technology may not help teens with the emotional and physical weight of managing the disease, study results show.

GLP-1 receptor agonists, used to manage diabetes, are now being used for obesity in children and adolescents.

The American Diabetes Association's 2023 “Children and adolescents: standards of care in diabetes” highlights risk factors and treatment for type 1 and type 2 diabetes.

In addition to approving these generics for children, adolescents and adults with ADHD, the generic chewable tablets and capsules are also approved for adults with moderate to severe binge-eating disorder.

Study authors conclude that all children should be up to date with recommended COVID-19 vaccines and initiate the vaccination process immediately when products become available.

Serotonin reuptake inhibitors (SSRIs) are the preferred medication to treat postnatal depression, but there is a lack of evidence about their long-term impact on women and their children.

A recent systematic review found no serious adverse events related to the use of cannabis for the management of cancer-related symptoms in children.

The respiratory syncytial virus vaccine (Abrysvo) is the first and only maternal RSV vaccine used to help protect infants from the virus.

According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023.

A study from Bavaria, Germany, found the frequency was higher among boys and children younger than the median age of 6.5 years during the pandemic.

Children who tested positive were more likely to report long COVID symptoms at 90 days than children who tested negative.

Investigators said that RSV-prevention products and socioeconomic determinants of health for AI/AN children are “urgently needed.”

Researchers hope a new study will alleviate patients and clinicians fear of prescribing stimulants for children with ADHD.

Numerous tools, technology platforms, and interventions have been developed to help teens with the difficult emotional and physical weight of managing the disease.

Although it is widely known that probiotics have anti-inflammatory effects and can alleviate clinical symptoms of atopic dermatitis (AD) in children, the effects of probiotics on AD in children have long been controversial.

The acceptance comes 5 days after the agency approved delandistrogene moxeparvovec-rokl to treat ambulatory pediatric DMD patients aged 4 to 5 years.

The accelerated approval of delandistrogene moxeparvovec-rokl is “based on expression of Elevidys micro-dystrophin observed in patients treated with ELEVIDYS,” according to Sarepta Therapeutics.

According to the FDA, the approvals “provide a new class of medicines taken by mouth to treat pediatric T2D.”